Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Biology Startup Synlogic Raises $29.4M in Series A Round

NEW YORK (GenomeWeb) – Synthetic biology startup Synlogic today announced it has raised $29.4 million in Series A financing.

Atlas Ventures and New Enterprise Associates led the round. Cambridge, Mass.-based Synlogic plans to use proceeds from the raise to further develop its microbial engineering platform for developing therapeutic microbes and advancing its preclinical pipeline across clinical applications, it said.

The company was co-founded last fall by Ankit Mahadevia, a venture partner at Atlas Ventures; Jim Collins a professor of biomedical engineering at Boston University; and Timothy Lu, an assistant professor of electrical engineering and biomedical engineering at the Massachusetts Institute of Technology. Collins and Lu have developed tools that allow bacteria to sense physiologic conditions, perform a therapeutic action, and deactivate themselves afterward. Those tools now underlie Synlogic's pipeline of therapeutics, the company said, adding that its platform "offers a unique modality to treat diseases where traditional, systemically delivered pharmaceuticals have not been successful."

The company noted that its technology could especially have value for therapeutics directed at gastrointestinal disorders.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.